Revolutionary Breakthrough in Neurodegenerative Disease Treatment

Researchers at the University of Essex have made a groundbreaking discovery that could pave the way for new approaches to treating neurodegenerative diseases such as Alzheimer’s, Parkinson’s, and motor neurone disease (MND).

Working with an international team, the scientists used artificial intelligence to create extremely small antibody fragments that can be produced directly inside human cells. These microscopic medicines, known as ‘intrabodies,’ can attach to proteins associated with disease, providing a new avenue for treatment.

The team, led by Dr. Caitlin O’Shea and Dr. Gareth Wright from the School of Life Sciences, used AI-powered protein redesign to convert 672 different antibodies into intrabodies capable of targeting important disease-related proteins.

The research was funded by the MND Association and has the potential to give scientists new ways to study and potentially treat neurodegenerative diseases by acting directly inside living cells, where many of the biological processes involved in these conditions begin.

Electrical Charge Plays a Crucial Role in Antibody Stability

The researchers discovered that electrical charge is a key factor in determining whether antibody fragments can remain stable and functional inside cells. This insight allowed them to redesign the antibodies to have the right charge and be super stable, making them suitable for use as intrabodies.

Dr. O’Shea explained, ‘We looked at the properties of millions of antibodies and compared them with human proteins found inside the cell. From this, we figured out that antibodies usually have the wrong charge to exist inside cells without sticking together.’

Dr. Wright added, ‘We’ve made intracellular antibodies that stick to proteins that cause neurodegenerative diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and motor neurone disease.’

Repurposing Millions of Existing Antibodies

The researchers believe that their findings could allow scientists to find new uses for millions of antibodies developed during decades of biomedical research. Rather than starting entirely from scratch, existing antibodies may be adaptable for use as powerful laboratory tools and, potentially, as the foundation for future treatments aimed at disease-causing proteins.

Dr. Wright said, ‘We’ve made a significant advance in overcoming one of the key challenges that has impeded the development of antibodies as treatments for neurodegenerative diseases, such as MND.’

The MND Association welcomed the findings and highlighted their potential importance for future treatments. Chief Scientist at the charity, Dr. Brian Dickie, said, ‘The research findings provide optimism that a combination of this novel ‘intrabody’ science with emerging gene therapy techniques may lead to new therapeutic strategies that can hit specific molecular targets within neurones.’

The redesigned molecules will be made freely available to other scientists following the publication of the research in Nature Communications.

New Therapeutic Possibilities for MND and Other Diseases

The researchers’ work has the potential to give scientists new ways to study and potentially treat neurodegenerative diseases by acting directly inside living cells, where many of the biological processes involved in these conditions begin.

The team’s discovery could lead to new therapeutic strategies for diseases that affect tens of millions of people around the world.

The advance could have major implications for diseases that affect over one million people in the UK alone, making it a big public health concern.